CD7-targeted chimeric antigen receptor-T (CAR-T) cell therapy has shown great promise in the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL). This evidence concerns the gene CD7 and T-cell acute lymphoblastic leukemia.